{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:48:16Z","timestamp":1769874496723,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":122,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"DOI":"10.1164\/rccm.202505-1146ed","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T18:14:41Z","timestamp":1752862481000},"page":"1895-1896","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":0,"title":["Elexacaftor\/Tezacaftor\/Ivacaftor in Children with Cystic Fibrosis: No Longer \u201cIf\u201d but a Question of \u201cWhen\u201d to Start"],"prefix":"10.1093","volume":"211","author":[{"given":"Hiran","family":"Selvadurai","sequence":"first","affiliation":[{"name":"The Children\u2019s Hospital at Westmead Sydney Children\u2019s Hospital Network Sydney, Australia"},{"name":"Discipline of Paediatrics and Child Health University of Sydney Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026013020473289500_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children \u22656 years with cystic fibrosis and at least one F508del allele: a 192-week, phase 3, open-label extension study","volume":"211","author":"Wainwright","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508 allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib3","article-title":"Long term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children \u22656 year with cystic fibrosis","year":"2023","journal-title":"Am J Resp Crit Care Med"},{"key":"2026013020473289500_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib5","article-title":"Immune responses in cystic fibrosis: are they intrinsically defective?","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026013020473289500_bib6","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508 del allele","author":"Zemanick","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026013020473289500_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1165\/rcmb.2019-0032OC","article-title":"Transcriptomic responses to ivacaftor and prediction of ivacaftor clinical responsiveness","volume":"61","author":"Sun","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026013020473289500_bib8","article-title":"Impact of Trikafta on lung function inflammation in preschool CF patients: MRI and biomarkers studies","author":"Orens","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2019.08.021","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026013020473289500_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508 del and a minimal function mutation: a phase 3b randomized placebo controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib11","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/jmri.27030","article-title":"Current state of the art MRI for the longitudinal assessment of cystic fibrosis","volume":"52","author":"Woods","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"2026013020473289500_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool age children with cystic fibrosis","volume":"404","author":"Sermaut-Gaudelus","year":"2024","journal-title":"Lancet"},{"key":"2026013020473289500_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00127-022-02307-w","article-title":"Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: a systematic review and metanalysis","volume":"58","author":"Lord","year":"2023","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2026013020473289500_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020473289500_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026013020473289500_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long term health outcomes in people with cystic fibrosis homozygous for deltaF508","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1895\/66621737\/ajrccm_211_10_1895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1895\/66621737\/ajrccm_211_10_1895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:47:38Z","timestamp":1769824058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/10\/1895\/8444276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202505-1146ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}